A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Phase 3 Completed 390 enrolled Lund University Hospital Sanofi · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.

Timeline

Start: 2008-06
Primary completion: 2017-05
Completion: 2017-05

Publications

Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M; Swedish Lung Cancer Study Group (SLUSG). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018 Feb 1;29(2):398-404. doi: 10.1093/annonc/mdx716.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enoxaparin sodium	Other / unclassified	1 mg/kg	Subcutaneous
Background	Carboplatin	Small molecule	—	—
Background	Cisplatin	Other / unclassified	—	—
Background	Etoposide	Small molecule	—	—

A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications